Skip to content
HowShorted

Clovis Oncology, Inc. short interest in 2019

In 2019, Clovis Oncology, Inc.'s disclosed short interest ran from 21.95% of shares outstanding on 15 Jan 2019 to 49.06% on 31 Dec 2019, a change of +27.11 percentage points. The year's high was 50.04% on 29 Nov 2019 and its low 15.30% on 15 May 2019, averaging 28.69% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.44 days on 14 Jun 2019. Full history: Clovis Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Clovis Oncology, Inc. in 2019

2019 in figures

Start of year
21.95% (15 Jan 2019)
End of year
49.06% (31 Dec 2019)
Change
+27.11 pp
High
50.04% (29 Nov 2019)
Low
15.30% (15 May 2019)
Average
28.69%
Highest days to cover
8.44 (14 Jun 2019)
SEC filings marked
9

Every report in 2019

Clovis Oncology, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201921.95%4.28results (8-K)
31 Jan 201923.26%6.43
15 Feb 201922.64%7.47
28 Feb 201920.30%4.36results (8-K), 10-K filed
15 Mar 201917.99%5.15
29 Mar 201917.10%6.45
15 Apr 201917.16%7.37
30 Apr 201916.53%6.35
15 May 201915.30%5.2610-Q filed, results (8-K)
31 May 201916.02%5.34
14 Jun 201916.25%8.44
28 Jun 201919.67%3.68
15 Jul 201921.11%7.09
31 Jul 201917.56%4.52
15 Aug 201931.97%2.56results (8-K), 10-Q filed
30 Aug 201938.32%6.84
13 Sep 201940.66%7.15
30 Sep 201937.98%4.31
15 Oct 201939.34%6.88
31 Oct 201940.21%5.61
15 Nov 201949.13%2.1010-Q filed, results (8-K)
29 Nov 201950.04%1.66
13 Dec 201948.99%1.50
31 Dec 201949.06%4.95

See also: Clovis Oncology, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.